Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
作者信息
Halford Sarah, Wan Susan, Dragoni Ilaria, Silvester Julie, Nazarov Bobojon, Anthony Daniel, Anthony Suzie, Ladds Emma, Norrie John, Dhaliwal Kevin
机构信息
Cancer Research UK Centre for Drug Development, London, UK.
Latus Therapeutics, London, UK.
出版信息
Trials. 2022 Apr 21;23(1):336. doi: 10.1186/s13063-022-06266-0.
Abstract
摘要
相似文献
1
Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.更正：SPIKE-1：一项在社区环境中进行的随机II/III期试验，评估使用卡莫司他通过阻断SARS-CoV-2刺突蛋白引发的膜融合来降低COVID-19临床进展的效果。
Trials. 2022 Apr 21;23(1):336. doi: 10.1186/s13063-022-06266-0.
2
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.SPIKE-1：一项在社区环境中进行的随机 II/III 期试验，评估了使用卡莫司他通过阻断 SARS-CoV-2 刺突蛋白引发的膜融合来减少 COVID-19 临床进展的效果。
Trials. 2021 Aug 19;22(1):550. doi: 10.1186/s13063-021-05461-9.
3
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
4
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.甲磺酸卡莫司他对半机械型药代动力学-药效动力学模型预测对 COVID-19 中 SARS-CoV-2 的疗效。
Microbiol Spectr. 2022 Apr 27;10(2):e0216721. doi: 10.1128/spectrum.02167-21. Epub 2022 Apr 12.
5
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.一项随机对照 2 期临床试验：口服卡莫司他与安慰剂治疗非住院轻至中度 2019 年冠状病毒病成人患者 1 周的疗效比较。
Clin Infect Dis. 2023 Oct 5;77(7):941-949. doi: 10.1093/cid/ciad342.
6
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.甲磺酸卡莫司他通过 TMPRSS2 相关蛋白酶抑制 SARS-CoV-2 的激活，其代谢产物 GBPA 发挥抗病毒活性。
EBioMedicine. 2021 Mar;65:103255. doi: 10.1016/j.ebiom.2021.103255. Epub 2021 Mar 4.
7
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.TMPRSS2 抑制剂那法莫司他可降低 COVID-19 小鼠模型中的 SARS-CoV-2 肺部感染。
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.
8
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.甲磺酸卡莫司他治疗 SARS-CoV-2 和 COVID-19 的作用机制、剂量和安全性。
Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):204-212. doi: 10.1111/bcpt.13533. Epub 2020 Nov 22.
9
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.一项关于口服甲磺酸卡莫司他早期治疗新冠门诊患者的2期随机、双盲、安慰剂对照试验显示病程缩短，嗅觉和味觉丧失减轻。
medRxiv. 2022 Jan 31:2022.01.28.22270035. doi: 10.1101/2022.01.28.22270035.
10
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.甲磺酸卡莫司他在门诊环境中早期 COVID-19 疾病中的疗效和安全性：一项随机安慰剂对照的 II 期试验。
Int J Infect Dis. 2022 Sep;122:628-635. doi: 10.1016/j.ijid.2022.06.054. Epub 2022 Jul 5.
本文引用的文献
1
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.SPIKE-1：一项在社区环境中进行的随机 II/III 期试验，评估了使用卡莫司他通过阻断 SARS-CoV-2 刺突蛋白引发的膜融合来减少 COVID-19 临床进展的效果。
Trials. 2021 Aug 19;22(1):550. doi: 10.1186/s13063-021-05461-9.
Zotero 插件